The Inflammatory C-Reactive Protein is Increased in Both Liver and Adipose Tissue in Severely Obese Patients Independently from Metabolic Syndrome, Type 2 Diabetes, and NASH

OBJECTIVE:C-Reactive Protein (CRP), a nonspecific marker of inflammation that is moderately elevated in obesity, metabolic syndrome (MS), and type 2 diabetes, has been proposed as a surrogate marker of nonalcoholic steatohepatitis (NASH). Its clinical usefulness in the diagnosis of NASH was evaluated in severely obese patients without or with MS, diabetes, and NASH and the potential roles of the liver and of the adipose tissue in CRP production were characterized.METHODS:Severely obese patients without NASH (without MS [N = 13], with MS [N = 11], or with MS and diabetes [N = 7]) and with NASH (without [N = 8] or with [N = 7] MS) were studied. For each patient, liver and adipose tissue biopsies were collected during a bariatric surgery and were used to determine the CRP gene expression by real-time PCR. The role of interleukin-6 (IL6) and lipopolysaccharide in CRP expression was also evaluated in subcutaneous adipose tissue obtained during cosmetic abdominoplasty.RESULTS:Plasma CRP levels were elevated in severely obese patients independently from the presence or absence of MS, diabetes, or NASH. CRP gene expression was not only increased in livers but also in adipose tissues of obese patients compared with controls subjects. In human adipose tissue, CRP mRNA levels were positively correlated with those of IL-6 and the CRP expression was enhanced in vitro by IL-6 and lipopolysaccharide.CONCLUSION:Plasma CRP levels are not predictive of the diagnosis of NASH in severely obese patients. The liver but also the adipose tissue can produce CRP, a process which could be dependent on IL6. Therefore, both tissues might contribute to the elevated plasma CRP levels found in obesity. In addition, the large amount of body fat may well produce an important part of the circulating CRP, further limiting its clinical usefulness in the evaluation of NASH in severely obese patients.

[1]  T. Komeda.  Obesity and NASH in Japan. , 2005, Hepatology research : the official journal of the Japan Society of Hepatology.

[2]  E. Yeh,et al.  Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: linking obesity to vascular inflammation. , 2005, Journal of the American College of Cardiology.

[3]  N. Assy,et al.  Elevated plasma protein C levels correlate with the presence of fatty liver (NASH and NAFLD) , 2005, Gut.

[4]  S. Daniels,et al.  Diet-induced weight loss is associated with decreases in plasma serum amyloid a and C-reactive protein independent of dietary macronutrient composition in obese subjects. , 2005, The Journal of clinical endocrinology and metabolism.

[5]  M. Rudemo,et al.  Evaluation of reference genes for studies of gene expression in human adipose tissue. , 2005, Obesity research.

[6]  G. Hitman,et al.  Association between fasting glucose and C-reactive protein in middle-aged subjects. , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[7]  I. S. Wood,et al.  Adipokines: inflammation and the pleiotropic role of white adipose tissue , 2004, British Journal of Nutrition.

[8]  E. Bruckert,et al.  Systemic low-grade inflammation is related to both circulating and adipose tissue TNFα, leptin and IL-6 levels in obese women , 2004, International Journal of Obesity.

[9]  H. Kim,et al.  Insulin resistance and C‐reactive protein as independent risk factors for non‐alcoholic fatty liver disease in non‐obese Asian men , 2004, Journal of gastroenterology and hepatology.

[10]  J. Levy,et al.  Use and abuse of HOMA modeling. , 2004, Diabetes care.

[11]  A. Madan,et al.  Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. , 2004, Endocrinology.

[12]  J. Kench,et al.  High sensitivity C‐reactive protein values do not reliably predict the severity of histological changes in NAFLD , 2004, Hepatology.

[13]  L. Tartaglia,et al.  Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. , 2003, The Journal of clinical investigation.

[14]  M. Desai,et al.  Obesity is associated with macrophage accumulation in adipose tissue. , 2003, The Journal of clinical investigation.

[15]  J. Kaski,et al.  The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. , 2003, Journal of the American College of Cardiology.

[16]  J. Capeau,et al.  Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. , 2003, Biochemical and biophysical research communications.

[17]  R. Paschke,et al.  Regulation of adipocytokines and insulin resistance , 2003, Diabetologia.

[18]  E. Yeh,et al.  Inflammatory Cytokines Stimulated C-Reactive Protein Production by Human Coronary Artery Smooth Muscle Cells , 2003, Circulation.

[19]  R. Bergman,et al.  Low insulin sensitivity (S(i) = 0) in diabetic and nondiabetic subjects in the insulin resistance atherosclerosis study: is it associated with components of the metabolic syndrome and nontraditional risk factors? , 2003, Diabetes care.

[20]  M. Duchrow,et al.  Local Generation of C-Reactive Protein in Diseased Coronary Artery Venous Bypass Grafts and Normal Vascular Tissue , 2003, Circulation.

[21]  S. Toubro,et al.  Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. , 2003, American journal of physiology. Endocrinology and metabolism.

[22]  K. Nakao,et al.  Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. , 2003, Diabetes care.

[23]  Mark B Pepys,et al.  C-reactive protein: a critical update. , 2003, The Journal of clinical investigation.

[24]  M. Berlan,et al.  Do regional differences in adipocyte biology provide new pathophysiological insights? , 2003, Trends in pharmacological sciences.

[25]  E. Minar,et al.  Impact of Weight Loss on Inflammatory Proteins and Their Association With the Insulin Resistance Syndrome in Morbidly Obese Patients , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[26]  B. Neuschwander‐Tetri,et al.  Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference , 2003, Hepatology.

[27]  M. Koruk,et al.  Serum levels of acute phase proteins in patients with nonalcoholic steatohepatitis. , 2003, The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology.

[28]  Hitoshi Nishizawa,et al.  Reciprocal Association of C-Reactive Protein With Adiponectin in Blood Stream and Adipose Tissue , 2003, Circulation.

[29]  P. Gerke,et al.  The kidney as a second site of human C‐reactive protein formation in vivo , 2003, European journal of immunology.

[30]  E. Poehlman,et al.  Weight Loss Reduces C-Reactive Protein Levels in Obese Postmenopausal Women , 2002, Circulation.

[31]  A. Minenna,et al.  C-reactive protein is independently associated with total body fat, central fat, and insulin resistance in adult women , 2001, International Journal of Obesity.

[32]  L. Heilbronn,et al.  Energy Restriction and Weight Loss on Very-Low-Fat Diets Reduce C-Reactive Protein Concentrations in Obese, Healthy Women , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[33]  P. Mcgeer,et al.  Generation of C-reactive protein and complement components in atherosclerotic plaques. , 2001, The American journal of pathology.

[34]  H. Brenner,et al.  Association between C-reactive protein and features of the metabolic syndrome: a population-based study. , 2000, Diabetes care.

[35]  C. Stehouwer,et al.  The influence of improved glycaemic control with insulin and sulphonylureas on acute phase and endothelial markers in Type II Diabetic subjects , 2000, Diabetologia.

[36]  S. Haffner,et al.  Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). , 2000, Circulation.

[37]  P. Giral,et al.  Liver fibrosis in overweight patients. , 2000, Gastroenterology.

[38]  G. Brandi,et al.  Prevalence of and Risk Factors for Hepatic Steatosis in Northern Italy , 2000, Annals of Internal Medicine.

[39]  M. Visser,et al.  Elevated C-reactive protein levels in overweight and obese adults. , 1999, JAMA.

[40]  E. Ford.  Body mass index, diabetes, and C-reactive protein among U.S. adults. , 1999, Diabetes care.

[41]  B. Neuschwander‐Tetri,et al.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions , 1999, American Journal of Gastroenterology.

[42]  A. Hofman,et al.  Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[43]  S. Coppack,et al.  C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[44]  I. Kushner,et al.  Acute-phase proteins and other systemic responses to inflammation. , 1999, The New England journal of medicine.

[45]  J S Yudkin,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1997 by The Endocrine Society Subcutaneous Adipose Tissue Releases Interleukin-6, But Not Tumor Necrosis Factor-�, in Vivo* , 2022 .

[46]  C. Tiribelli,et al.  Prevalence of chronic liver disease in the general population of northern Italy: The dionysos study , 1994, Hepatology.

[47]  B. Neuschwander‐Tetri,et al.  Nonalcoholic steatohepatitis: an expanded clinical entity. , 1994, Gastroenterology.

[48]  B. Klein,et al.  C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo. , 1992, Arthritis and rheumatism.

[49]  J V Castell,et al.  Interleukin-6 and the acute phase response. , 1990, The Biochemical journal.

[50]  C. Hsieh,et al.  Orlistat for obesity: benefits beyond weight loss. , 2005, Diabetes research and clinical practice.

[51]  J. Amado,et al.  Effects of changes in body weight and insulin resistance on inflammation and endothelial function in morbid obesity after bariatric surgery. , 2005, The Journal of clinical endocrinology and metabolism.

[52]  M. Cushman,et al.  Menopause-related differences in inflammation markers and their relationship to body fat distribution and insulin-stimulated glucose disposal. , 2002, Fertility and sterility.

[53]  G. Marchesini,et al.  Clinical Features and Natural History of Nonalcoholic Steatosis Syndromes , 2001, Seminars in liver disease.

[54]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.

[55]  F. Schaffner,et al.  Nonalcoholic fatty liver disease. , 1986, Progress in liver diseases.